Approval · Notice of Compliance 14271 · 2013
SERC: Notice of Compliance 14271
Issued April 10, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14271
- Date
- April 10, 2013
- Company
- Abbott Laboratories Co.Saint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New format of the Product Monograph including safety updates
- Therapeutic class
- Anti-vertigo agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SERC | Not yet assigned | — |
Medicinal ingredients
- BETAHISTINE HYDROCHLORIDE 16 MG per TAB
- BETAHISTINE HYDROCHLORIDE 24 MG per TAB